# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.
OncoCyte (NASDAQ:OCX) reported quarterly losses of $(1.13) per share which missed the analyst consensus estimate of $(0.67) by ...
Needham analyst Mike Matson maintains OncoCyte (NASDAQ:OCX) with a Buy and raises the price target from $3.6 to $4.25.
- SEC Filing
Stephens & Co. analyst Mason Carrico reiterates OncoCyte (NASDAQ:OCX) with a Equal-Weight and maintains $4 price target.
Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new d...
Benchmark analyst Bruce Jackson reiterates OncoCyte (NASDAQ:OCX) with a Speculative Buy and maintains $5 price target.